INTERESTED IN BREAST CANCER NEWS?

Sign up for CURE's breast cancer newsletter and you'll receive CURE's coverage of the San Antonio Breast Cancer Symposium, a leading conference for researchers and advocates.

You can also follow coverage throughout the meeting by reading blogs from Dr. Debu Tripathy and other CURE staff.

[SIGN UP FOR BREAST CANCER NEWS]

Blogs

DEBU TRIPATHY, MD, EDITOR-IN-CHIEF, BREAST ONCOLOGIST

Dr. Tripathy, the editor-in-chief of CURE, is a practicing breast oncologist and co-leader of the Women's Cancer Program at Norris Comprehensive Cancer Center at the University of Southern California. He will help put this year's SABCS research into context for patients and survivors. [READ HIS BLOG]

ELIZABETH WHITTINGTON, CURETODAY.COM EDITOR

Elizabeth will be covering the scientific presentations and poster sessions for CURE magazine and Curetoday.com. She'll also be on the lookout for advocates during the meeting to provide insight and information for other patients and survivors. [READ HER BLOG]

You can follow all this year's SABCS-related blogs at curetoday.com/blog/SABCS11.

News from SABCS

• Dual HER2 Blockade Significantly Extends Progression-Free Survival
• Addition of Bevacizumab to Conventional Therapy Improved Progression-Free Survival in HER2-Positive Breast Cancer
• Exemestane Plus Everolimus Increased Progression-Free Survival for Women With Metastatic Breast Cancer
• Brachytherapy Was Associated With Twofold Increased Risk for Mastectomy, Complications
• New Test Predicts Risk for Recurrence for Patients With DCIS
• Molecular Differences May Be Used to Predict Early vs. Late Hormone Receptor-Positive Breast Cancer Recurrence

Community

Feel free to join in the conversation or start your own on:

Facebook > What news are you interested in hearing at SABCS?

Message Boards > Are you involved in advocacy?

Twitter > Join the conversation by following #sabcs

Become a fan of CURE on Facebook.

Follow CURE on Twitter.

Send feedback to editor@curetoday.com.

Sign up for our email newsletters, which you can now personalize by tumor type, survivorship or caregiver status.

This email was sent to you because you have provided your email address to CURE. CURE is committed to protecting your privacy, and no information about our subscribers is sold to any outside party.

Please add enews@curetoday.com to your address book or safe sender list to ensure this email is delivered to your inbox.

2011 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic or treatment advice.